Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 87

Sort by

Sort Order Select

Journal Articles

Addressing Unmet Needs in the Management of Drug-Induced Secondary Erythrocytosis: Results from an International Physician Survey

Natasha Szuber, Lambert Busque, Harold J. Olney, Luigina Mollica, Shireen Sirhan

Blood (2024) 144 (Supplement 1): 7697.

https://doi.org/10.1182/blood-2024-207623

Published: 2024

Journal Articles

Sex-Related Differences in CML Outcomes in a Real-World Prospective Registry (GQR LMC-NMP)

Marc-Etienne Beaudet, Natasha Szuber, Hanane Moussa, Michaël Harnois, Sarit E. Assouline, Lambert Busque

Blood (2024) 144 (Supplement 1): 533.

https://doi.org/10.1182/blood-2024-204342

Published: 2024

Journal Articles

Distinguishing Germline from Acquired Pathogenic CSF3R Variants: Key Diagnostic Features and Clinical Implications

Janick Caron-L'Ecuyer, Michaël Harnois, Marie-Christine Meunier, Vincent Ethier, Genevieve Huynh-Trudeau, Lissa Ajjamada, Lambert Busque, Natasha Szuber

Blood (2024) 144 (Supplement 1): 1783.

https://doi.org/10.1182/blood-2024-198896

Published: 2024

Journal Articles

Understanding the Lived Experience of Fatigue in Adolescents and Young Adults with Myeloproliferative Neoplasms: A Mixed Methods Study

Steve Dagenais-Bellefeuille, Karine Bilodeau, Alisa Poullet, Shireen Sirhan, Robert Delage, Ghislain Cournoyer, Ines Chamakhi, Danielle Talbot, Luigina Mollica, Daniele Marceau, Vincent Ethier, Pierre Desjardins, Harold J. Olney, Michaël Harnois, Lambert Busque, Natasha Szuber

Blood (2024) 144 (Supplement 1): 408.

https://doi.org/10.1182/blood-2024-206225

Published: 2024

Journal Articles

CALR mutation burden in essential thrombocythemia and disease outcome

Paola Guglielmelli, Natasha Szuber, Naseema Gangat, Giulio Capecchi, Chiara Maccari, Michaël Harnois, Omer Karrar, Maymona Abdelmagid, Manjola Balliu, Elena Nacca, Alessandro Atanasio, Ilaria Sestini, Audrey Désilets, Giuseppe Gaetano Loscocco, Giada Rotunno, Lambert Busque, Ayalew Tefferi, Alessandro Maria Vannucchi

Blood (2024) 143 (13): 1310–1314.

https://doi.org/10.1182/blood.2023023428

Published: 2024

Includes: Supplemental data

Journal Articles

Prospective Symptom Burden Analysis in 784 Patients with Myeloproliferative Neoplasms: High Burden Correlates with Inflammatory/Genetic Biomarkers and Reduced Survival

Alisa Poullet, Lambert Busque, Shireen Sirhan, Robert Delage, Ghislain Cournoyer, Ines Chamakhi, Danielle Talbot, Luigina Mollica, Daniele Marceau, Vincent Ethier, Pierre Desjardins, Harold J. Olney, Michaël Harnois, Natasha Szuber

Blood (2023) 142 (Supplement 1): 917.

https://doi.org/10.1182/blood-2023-183005

Published: 2023

Journal Articles

Calr Variant Allele Frequency in Essential Thrombocythemia: Molecular Associations and Impact on Disease Phenotype and Outcome

Paola Guglielmelli, Natasha Szuber, Naseema Gangat, Giulio Capecchi, Chiara Maccari, Lambert Busque, Omer Karrar, Maymona Abdelmagid, Manjola Balliu, Alessandro Atanasio, Ilaria Sestini, Audrey Desilets, Giuseppe Gaetano Loscocco, Giada Rotunno, Marie-Christine Meunier, Michael Harnois, Ayalew Tefferi, Alessandro Maria Vannucchi

Blood (2023) 142 (Supplement 1): 6328.

https://doi.org/10.1182/blood-2023-174076

Published: 2023

Journal Articles

Perioperative Outcomes and Management in Patients with Myeloproliferative Neoplasms: A Multicentric Retrospective Analysis of 354 Surgical Interventions

Natasha Szuber, Steve Dagenais-Bellefeuille, Mégane Tanguay, Awatef Shehabeldeen, Saima Ahmed, Michaël Harnois, Jaroslav F. Prchal, Harold J. Olney, Lambert Busque, Shireen Sirhan

Blood (2023) 142 (Supplement 1): 3183.

https://doi.org/10.1182/blood-2023-188259

Published: 2023

Journal Articles

Reclassification of Ascertain (ASTX727-02) Myelodysplastic Syndrome (MDS) Patients: Outcomes Including Clinical Response, Overall Survival (OS), and Leukemia Free Survival (LFS) Based on IPSS-R and IPSS-M Scoring Systems

Blood (2023) 142 (Supplement 1): 4619.

https://doi.org/10.1182/blood-2023-188258

Published: 2023

Journal Articles

Prognostic Impact of High Calreticulin Variant Allele Frequency in Patients with Myeloproliferative Neoplasms

Audrey Desilets, Michael Harnois, Lambert Busque, Natasha Szuber

Blood (2022) 140 (Supplement 1): 9700–9701.

https://doi.org/10.1182/blood-2022-163785

Published: 2022

Journal Articles

Ex Vivo Generation and Infusion of Anti-Minor Histocompatibility Antigen Expanded T Cells for Patients Who Relapse after Allogeneic HLA-Matched Stem Cell Transplantation

Blood (2022) 140 (Supplement 1): 1601–1603.

https://doi.org/10.1182/blood-2022-170147

Published: 2022

Journal Articles

Prolonged Survival in Bi-Allelic TP53 -Mutated ( TP53 mut) MDS Subjects Treated with Oral Decitabine/Cedazuridine in the Ascertain Trial (ASTX727-02)

Blood (2022) 140 (Supplement 1): 2066–2069.

https://doi.org/10.1182/blood-2022-163841

Published: 2022

Journal Articles

Gaps in the Assessment and Monitoring of Cardiovascular Risk and Psychological Burden in Polycythemia Vera: Landmark 2.0, a Worldwide Health Survey

Blood (2022) 140 (Supplement 1): 12162–12164.

https://doi.org/10.1182/blood-2022-162516

Published: 2022

Journal Articles

Risk Factor Analysis for Second Treatment-Free Remission Failure from the Canadian TKI Discontinuation (TRAD) Trial in CML Patients: Treatment-Free Remission Accomplished By Dasatinib

Maria Agustina Perusini, Eshetu G. Atenafu, Donna L. Forrest, Bence-Bruckler Isabelle, Lynn Savoie, Mary-Margaret Keating, Lambert Busque, Robert Delage, Anargyros Xenocostas, Elena Liew, Pierre Laneuville, Kristjan Paulson, Tracy L. Stockley, Jeffrey H. Lipton, Brian Leber, Dennis Dong Hwan Kim

Blood (2022) 140 (Supplement 1): 6778–6779.

https://doi.org/10.1182/blood-2022-167581

Published: 2022

Journal Articles

Higher Rates of Perioperative Thrombosis and Distinct Management Practices in Secondary Erythrocytosis Versus Polycythemia Vera

Natasha Szuber, Michael Harnois, Robert Delage, Shireen Sirhan, Lambert Busque

Blood (2022) 140 (Supplement 1): 5661–5663.

https://doi.org/10.1182/blood-2022-170026

Published: 2022

Journal Articles

A macaque clonal hematopoiesis model demonstrates expansion of TET2-disrupted clones and utility for testing interventions

Blood (2022) 140 (16): 1774–1789.

https://doi.org/10.1182/blood.2021014875

Published: 2022

Includes: Supplemental data

Journal Articles

Real-Life Use of Nilotinib for Chronic Phase CML Demonstrates Similar Efficacy and Rate of Cardiovascular Events As Enestnd

Olivier Del Corpo, Michael Harnois, Lambert Busque, Sarit Assouline

Blood (2021) 138 (Supplement 1): 4602.

https://doi.org/10.1182/blood-2021-151761

Published: 2021

Journal Articles

Oral Decitabine/Cedazuridine in Patients with Lower Risk Myelodysplastic Syndrome: A Longer-Term Follow-up of from the Ascertain Study

Blood (2021) 138 (Supplement 1): 66.

https://doi.org/10.1182/blood-2021-144648

Published: 2021

Journal Articles

Very Elderly Patients with Myeloproliferative Neoplasms: Phenotypic Distinctions and Prognostic Determinants of Complications and Mortality

Judith Jolin, Michael Harnois, Luigina Mollica, Pierre Laneuville, Robert Delage, Harold J. Olney, Shireen Sirhan, Lambert Busque, Natasha Szuber

Blood (2021) 138 (Supplement 1): 2572.

https://doi.org/10.1182/blood-2021-145131

Published: 2021

Journal Articles

Characteristics of High-Risk Polycythemia Vera Patients with Suboptimal Response to First-Line Therapy Who Switched to Ruxolitinib Vs Those Who Did Not Switch: Findings from PV-Switch, a Multinational, Retrospective Chart Review Study

Steffen Koschmieder, Clemens Schulte, Eyck von der Heyde, Lambert Busque, Françoise Boyer-Perrard, Timothy Devos, Francesco Passamonti, Mike W. Zuurman, Carole Paley, Geralyn Gilotti, Wendy Y. Cheng, Chi Gao, Mu Cheng, Melody Wu, Mei Sheng Duh, Claire N. Harrison

Blood (2021) 138 (Supplement 1): 3646.

https://doi.org/10.1182/blood-2021-148254

Published: 2021

NARROW

Addressing Unmet Needs in the Management of Drug-Induced Secondary Erythrocytosis: Results from an International Physician Survey

Sex-Related Differences in CML Outcomes in a Real-World Prospective Registry (GQR LMC-NMP)

Distinguishing Germline from Acquired Pathogenic CSF3R Variants: Key Diagnostic Features and Clinical Implications

Understanding the Lived Experience of Fatigue in Adolescents and Young Adults with Myeloproliferative Neoplasms: A Mixed Methods Study

CALR mutation burden in essential thrombocythemia and disease outcome

Prospective Symptom Burden Analysis in 784 Patients with Myeloproliferative Neoplasms: High Burden Correlates with Inflammatory/Genetic Biomarkers and Reduced Survival

Calr Variant Allele Frequency in Essential Thrombocythemia: Molecular Associations and Impact on Disease Phenotype and Outcome

Perioperative Outcomes and Management in Patients with Myeloproliferative Neoplasms: A Multicentric Retrospective Analysis of 354 Surgical Interventions

Reclassification of Ascertain (ASTX727-02) Myelodysplastic Syndrome (MDS) Patients: Outcomes Including Clinical Response, Overall Survival (OS), and Leukemia Free Survival (LFS) Based on IPSS-R and IPSS-M Scoring Systems

Prognostic Impact of High Calreticulin Variant Allele Frequency in Patients with Myeloproliferative Neoplasms

Ex Vivo Generation and Infusion of Anti-Minor Histocompatibility Antigen Expanded T Cells for Patients Who Relapse after Allogeneic HLA-Matched Stem Cell Transplantation

Prolonged Survival in Bi-Allelic TP53 -Mutated ( TP53 mut) MDS Subjects Treated with Oral Decitabine/Cedazuridine in the Ascertain Trial (ASTX727-02)

Gaps in the Assessment and Monitoring of Cardiovascular Risk and Psychological Burden in Polycythemia Vera: Landmark 2.0, a Worldwide Health Survey

Risk Factor Analysis for Second Treatment-Free Remission Failure from the Canadian TKI Discontinuation (TRAD) Trial in CML Patients: Treatment-Free Remission Accomplished By Dasatinib

Higher Rates of Perioperative Thrombosis and Distinct Management Practices in Secondary Erythrocytosis Versus Polycythemia Vera

A macaque clonal hematopoiesis model demonstrates expansion of TET2-disrupted clones and utility for testing interventions

Real-Life Use of Nilotinib for Chronic Phase CML Demonstrates Similar Efficacy and Rate of Cardiovascular Events As Enestnd

Oral Decitabine/Cedazuridine in Patients with Lower Risk Myelodysplastic Syndrome: A Longer-Term Follow-up of from the Ascertain Study

Very Elderly Patients with Myeloproliferative Neoplasms: Phenotypic Distinctions and Prognostic Determinants of Complications and Mortality

Characteristics of High-Risk Polycythemia Vera Patients with Suboptimal Response to First-Line Therapy Who Switched to Ruxolitinib Vs Those Who Did Not Switch: Findings from PV-Switch, a Multinational, Retrospective Chart Review Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only